Captrust Financial Advisors Has $553,000 Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Captrust Financial Advisors boosted its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 9.5% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 4,965 shares of the specialty pharmaceutical company’s stock after purchasing an additional 430 shares during the quarter. Captrust Financial Advisors’ holdings in Jazz Pharmaceuticals were worth $553,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in JAZZ. Itau Unibanco Holding S.A. bought a new position in Jazz Pharmaceuticals in the second quarter valued at about $29,000. EverSource Wealth Advisors LLC raised its stake in shares of Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 97 shares in the last quarter. Gladius Capital Management LP acquired a new position in shares of Jazz Pharmaceuticals during the 2nd quarter worth approximately $33,000. GAMMA Investing LLC grew its holdings in Jazz Pharmaceuticals by 41.3% in the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 121 shares in the last quarter. Finally, Venturi Wealth Management LLC grew its holdings in shares of Jazz Pharmaceuticals by 577.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after purchasing an additional 704 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Trading Up 0.5 %

JAZZ opened at $120.72 on Thursday. The business has a 50 day simple moving average of $116.81 and a two-hundred day simple moving average of $111.91. The firm has a market capitalization of $7.30 billion, a price-to-earnings ratio of 17.00, a PEG ratio of 1.04 and a beta of 0.57. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $134.17.

Insiders Place Their Bets

In related news, EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the sale, the executive vice president now owns 33,048 shares in the company, valued at $4,078,453.68. This represents a 10.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $121.17, for a total value of $242,340.00. Following the completion of the sale, the chief executive officer now owns 427,025 shares in the company, valued at $51,742,619.25. The trade was a 0.47 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 6,753 shares of company stock worth $816,289. Company insiders own 4.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on JAZZ. TD Cowen dropped their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Robert W. Baird raised their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. JPMorgan Chase & Co. raised their target price on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research note on Monday, August 19th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. Three investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $175.33.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.